文献速递皮肤肿瘤

辅助抗PD-1治疗对III期黑色素瘤五年生存影响的全国队列研究

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-08-31

该研究基于丹麦全国登记数据,比较辅助抗PD-1治疗实施前后III期黑色素瘤患者的5年总生存和黑色素瘤特异性死亡率。总体人群未见差异,但匹配分析中接受治疗者5年OS较高(80.3% vs 71.7%;HR 0.67,95%CI 0.47-0.95),疾病特异性结局不确定,把握度有限。

要点

  • 总体人群层面,辅助抗PD-1实施前后5年OS和MSM无差异。
  • 匹配分析中辅助抗PD-1与更高5年OS相关(80.3% vs 71.7%)。
  • MSM和隐匿淋巴结病变亚组结果不确定,把握度有限。

核心结论

  • 总体人群未能证实在引入辅助抗PD-1后生存改善,但匹配分析显示治疗患者OS更高。
  • 疾病特异性结局的不确定性和有限把握度使结论不明确。

研究设计与样本

  • 实施后队列中接受辅助抗PD-1的患者与实施前队列患者进行倾向性评分匹配。

主要发现

  • 两个队列中位随访均超过5年。
  • 总体人群层面,两个总队列间5年OS或MSM无差异。
  • 实施后队列中297例(53.8%)接受辅助抗PD-1。
  • 匹配后(每组n=279),辅助抗PD-1与更高5年OS相关(80.3% vs 71.7%;HR 0.67,95%CI 0.47-0.95;p=0.022)。
  • 5年MSM估计不确定(16.6% vs 20.8%,HR 0.77,95%CI 0.52-1.14;p=0.24)。

关键数值与推荐

  • 匹配分析5年OS:80.3% vs 71.7%(HR 0.67,95%CI 0.47-0.95;p=0.022)。
  • 5年MSM:16.6% vs 20.8%(HR 0.77,95%CI 0.52-1.14;p=0.24)。
  • 隐匿淋巴结病变匹配患者OS HR 0.70(95%CI 0.46-1.06),结果不确定。

临床怎么用

  • 辅助治疗决策需仔细个体化,并与患者充分讨论。
  • 在成熟试验数据明确辅助治疗角色前,应结合新兴新辅助策略综合考量。

局限性

  • 可用事件数有限,敏感性把握度分析提示仅能检测到大效应。
  • 治疗患者非黑色素瘤死亡风险也更低,提示匹配后仍可能存在健康差异,部分生存差异或非治疗效应。
  • 疾病特异性结局不确定,无法得出确切结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant anti-PD-1 therapy improves recurrence-free survival in resected stage III melanoma, but its impact on survival remains uncertain. OBJECTIVE: To evaluate the association of adjuvant anti-PD-1 therapy with overall survival (OS) and melanoma-specific mortality (MSM) in patients with stage III melanoma. METHODS: Five-year OS and MSM were compared between stage III melanoma patients diagnosed before (pre-cohort: June 2016-May 2018, n = 450) and after (post-cohort: January 2019-December 2020, n = 552) implementation of adjuvant anti-PD-1 in Denmark. Post-cohort patients receiving adjuvant anti-PD-1 were propensity score-matched to pre-cohort patients. RESULTS: Median follow-up exceeded 5 years in both cohorts. At the population level, no difference in 5-year OS or MSM was demonstrated between the total cohorts. In the post-cohort, 297 patients (53.8%) received adjuvant anti-PD-1. After matching (n = 279 per group), adjuvant anti-PD-1 was associated with higher 5-year OS (80.3% vs. 71.7%; HR 0.67, 95% CI 0.47-0.95; p = 0.022). 5-year MSM estimates were inconclusive (16.6% vs. 20.8%, HR 0.77, 95% CI 0.52-1.14; p = 0.24). Among matched patients with occult nodal disease, results were also inconclusive (OS HR 0.70, 95% CI 0.46-1.06). Sensitivity power analyses indicated that only large effects were detectable given the available events. CONCLUSIONS: We were unable to demonstrate an improved survival at the population level after adjuvant anti-PD-1 introduction, but matched analysis showed higher OS in treated patients. However, uncertainty in disease-specific outcomes and limited power preclude firm conclusions. Mature trial data are essential for defining the role of adjuvant therapy alongside emerging neoadjuvant strategies. Until then, carefully individualized adjuvant treatment decisions are of particular importance. Melanoma is a skin cancer that can spread to nearby lymph nodes, classifying it as stage III disease, which worsens prognosis. Since late 2018, anti‐PD‐1 immunotherapy has been approved in Denmark as adjuvant therapy for stage III melanoma, meaning treatment given after surgery. This therapy has shown to reduce the risk of cancer returning; however, whether it prolongs survival remains uncertain. Using nationwide Danish health registry data, we examined whether adjuvant immunotherapy is associated with improved survival in stage III melanoma. We studied 1002 patients diagnosed before (2016–2018) and after (2019–2020) adjuvant therapy became available. In the latter group, 297 of 552 patients received adjuvant anti‐PD‐1, and these treated patients were matched to similar untreated patients from the earlier period. Across the two periods, survival was not clearly different. But when comparing treated patients directly with similar untreated patients, more of the treated patients were alive after 5 years (80% vs. 72%), and fewer appeared to die from melanoma, pointing towards a possible benefit. Two findings, however, make this finding uncertain. First, the number of patients and deaths was too small to be sure the difference is real rather than due to chance. Second, treated patients were also less likely to die from causes unrelated to melanoma. This suggests they may have been healthier overall despite matching, and that part of the survival difference may reflect this rather than a treatment effect. Until clinical trials confirm whether adjuvant therapy extends survival, treatment decisions should be carefully discussed with each patient.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Weitemeyer MB, Helvind NM, Khan S, et al. Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma. J Eur Acad Dermatol Venereol. 2026. PMID: 42670281. doi:10.1111/jdv.70692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。